Developer docs
API playgroundTry for free, no card

Search company profiles

BioClavis

Full company profile

uuid0028sh8

Namestring
BioClavis
Legal namestring
BioClavis, Ltd.
Websiteurl
bioclavis.co.uk
Company typeenum
Private
Founded yearint
2017
Descriptiontext

BioClavis, Ltd. is a Glasgow-based (Clydebank) privately held R&D and services laboratory founded in 2017 as a UK/European spin-out of US-based BioSpyder Technologies Inc., with shared founder/CEO Joel McComb across both entities. The company operates a single-site services model at Carus House, Clydebank, with a disclosed headcount of 1-10 employees and no disclosed external venture or private equity backing.

The company's core asset is the licensed TempO-Seq platform — a proprietary targeted-sequencing transcriptomic technology protected by an extensive multi-jurisdictional patent portfolio (US, UK, Europe, Singapore, Australia, Canada, India, New Zealand). TempO-Seq uses detector oligos that hybridize directly to expressed transcripts, eliminating the need for RNA extraction or reverse transcription and enabling profiling from difficult sample types including FFPE tissue (validated up to 30+ years old), crude cell lysates, whole blood, dried blood spots, and single cells. Product variants built on this core chemistry include TempO-LINC (single-cell, launched February 2024), TempO-SPan (high-throughput diagnostic testing including COVID-19), TempO-Seq FFPE, TempO-Seq Dried Blood Spot, and TempO-Seq miRNA, supported by modular pre-designed and custom gene panels and the TempO-Seq Portal cloud analysis tool.

BioClavis generates revenue primarily through professional services — molecular profiling, bioinformatics, and contract research for pharmaceutical drug discovery and companion diagnostic development, academic researchers, and clinical research organizations — supplemented historically by a £30/sample COVID-19 testing service launched December 2020. Distribution of TempO-Seq kits is handled via an authorized distributor network covering Spain, South Korea, Japan, Hong Kong, and Thailand, with BioSpyder Inc. serving North America. Strategic positioning is reinforced through participation in EU-funded consortia including RISK-HUNT3R (Horizon2020, 2021) and BRECISE (IHI/Horizon Europe, 2025).

Short descriptiontext

BioClavis is a Glasgow-based R&D and services lab operating the proprietary TempO-Seq targeted-sequencing platform under license from parent BioSpyder Technologies, offering molecular profiling, biomarker discovery, and companion diagnostic services to pharmaceutical, academic, and clinical research customers across the UK, Europe, and APAC.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersClydebank, United Kingdom
HQ citystring
Clydebank
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
transcriptomic profiling services, targeted gene expression, biomarker discovery services, companion diagnostic development, high-throughput sequencing
Industry4 codes
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomics Services
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Molecular Profiling Services
TypeProfessional Services
Description

Lab services providing TempO-Seq transcriptomic and genomic analysis for drug discovery, biomarker discovery, and precision medicine applications. Services include high-throughput transcriptomics, companion diagnostic development, and clinical research support.

bioclavis.co.uk
2Bioinformatics Services
TypeProfessional Services
Description

Additional analysis services including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.

bioclavis.co.uk
3COVID-19 Testing Services
TypeProfessional Services
Description

TempO-SPan based COVID-19 testing service offered to businesses and organizations at £30 per sample price point for routine screening.

bioclavis.co.uk
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Marketing or Sales
Pricing details1 tier
1COVID-19 Testing Service
ModelUsage-basedBilling cadencePay-as-you-go
Notes

£30 per sample for routine COVID-19 testing service. Price available to companies and organizations subscribing to routine service. Government pricing offered at further discounted rates for excess capacity supporting public health efforts.

bioclavis.co.uk
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1TempO-Seq
Description

High-throughput targeted-sequencing transcriptomic/genomic platform technology for molecular analysis

bioclavis.co.uk
+3 more records
Core offering1 text field

BioClavis operates a Glasgow-based R&D and services laboratory that delivers TempO-Seq-based molecular profiling to pharmaceutical, academic, and clinical research customers. The company provides high-throughput transcriptomics, biomarker discovery, companion diagnostic development, and COVID-19 variant surveillance, packaged with cloud bioinformatics through the TempO-Seq Portal. Its offerings also include customizable gene-expression panels, dried blood spot and FFPE workflows, and the TempO-LINC single-cell platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • R2 = 0.97 correlation between FFPE and fresh frozen samples
+4 more records
Product overview1 text field

BioClavis offers a unified platform-plus-services model centered on TempO-Seq, a proprietary high-throughput targeted-sequencing transcriptomic technology that eliminates the need for RNA extraction or reverse transcription. The core TempO-Seq platform serves as the foundation for specialized assay products including TempO-Seq Dried Blood Spot (DBS), TempO-Seq FFPE, and TempO-Seq miRNA, each adapted for specific sample types. TempO-LINC extends the platform into single-cell genomics applications. The company provides modular assay panels (Whole Transcriptome, S1500+ Surrogate, PanCancer, and Custom) for multiple species, supported by bioinformatics services including probe design, differential expression analysis, and machine learning classification. Services span pharma (drug discovery, companion diagnostics), academic research, and clinical research applications. The ecosystem is unified by TempO-Seq Portal cloud-based data analysis software.

Product and service10 records
1TempO-Seq
CategoryTranscriptomics / Molecular Profiling
Description

Targeted, high-throughput transcriptomics platform using Detector Oligo chemistry to profile gene expression in a single assay, sold as a profiling service and kit to pharmaceutical and academic researchers.

2TempO-LINC
CategorySingle-Cell Transcriptomics
Description

Single-cell gene-expression profiling platform built on combinatorial split-pool barcoding, extending TempO-Seq chemistry to individual cells for pharma and academic customers.

3TempO-Span
CategoryDiagnostic Testing Service
Description

SARS-CoV-2 testing and variant surveillance panel built on TempO-Seq chemistry, offered as a per-sample COVID-19 testing service with results delivered through the TempO-Seq Portal.

4TempO-Seq Portal
CategoryBioinformatics Software
Description

Cloud-based bioinformatics platform that performs QC and gene-expression analysis on TempO-Seq data and delivers standardized reporting to research and clinical customers.

5Pharma Services
CategoryContract Research Services
Description

Dedicated TempO-Seq profiling service for pharmaceutical R&D teams, supporting drug discovery, mechanism-of-action studies, lead prioritization, and translational biomarker work.

6Academic Research Services
CategoryContract Research Services
Description

TempO-Seq profiling services tailored for academic and university research groups, including customizable panels and cloud-based analysis via the TempO-Seq Portal.

7Clinical Research Services
CategoryContract Research Services
Description

TempO-Seq clinical research service designed for clinical research organizations and translational sponsors needing validated profiling of FFPE and other clinical samples.

8Bioinformatics Services
CategoryBioinformatics Services
Description

Bespoke bioinformatics and gene-expression analysis services delivered alongside TempO-Seq profiling projects, with reporting routed through the TempO-Seq Portal.

9Personalised Diagnostics
CategoryDiagnostic Development Services
Description

Bespoke diagnostic development service that applies TempO-Seq chemistry to build companion and personalised diagnostics for pharmaceutical and clinical partners.

10High-Throughput Transcriptomics (HTTr)
CategoryContract Research Services
Description

Scalable, high-volume gene-expression profiling service using TempO-Seq chemistry for customers requiring large numbers of samples and reproducible data turnaround.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

BioClavis joined the BRECISE project as an industry partner - a five-year research initiative co-funded by the Innovative Health Initiative (IHI) and Horizon Europe. The project focuses on precision oncology for prostate and bladder cancer using NGS-based multi-modality AI biomarkers. BioClavis contributes TempO-Seq for molecular analysis and biomarker identification.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

BioClavis joined the Horizon2020-funded RISK-HUNT3R project alongside 36 partners including academic researchers, regulatory authorities, and safety scientists from Pharma and Cosmetics sectors. The five-year project aims to develop animal-free chemical safety assessment methods using TempO-Seq for high-throughput transcriptomics on in vitro cell models.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2017-01-01
Description

BioClavis is a spin-out of US-based BioSpyder Technologies. The company leverages the proprietary TempO-Seq targeted-sequencing transcriptomic/genomic platform technology under license for precision diagnostics and drug discovery services. Joel McComb is CEO and founder of both companies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

BioClavis maintains close collaborations with NHS and academic researchers to develop diagnostic solutions at the center of patient and healthcare system needs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

BioSpyder actively seeks collaborators in Liquid Biopsy, Toxicology/Metabolism, Oncology, Mental Health, Metabolic Diseases, Allergy, Host Defense, and Agriculture for TempO-Seq applications.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Part of Eurofins Scientific, one of the world's largest genomics services providers offering DNA/RNA sequencing, oligonucleotide synthesis, and bioinformatics. Comparable as a broader-scale genomics services lab serving pharma and academic customers with overlapping transcriptomics offerings.

TypeDirect peer
Description

Leading single-cell genomics platform company offering Chromium and Visium products. Direct competitor to BioClavis's newly launched TempO-LINC single-cell platform with overlapping pharma and translational research customers.

TypeDirect peer
Description

Developer of mass cytometry and single-cell genomics platforms including the Hyperion and Biomark systems. Direct competitor in high-throughput single-cell and targeted transcriptomics for pharma and academic research applications.

TypeBroad incumbent
Description

Dominant sequencing platform vendor whose instruments underpin most RNA-seq and targeted sequencing workflows. Comparable as the underlying sequencing technology provider whose installed base defines the competitive context for TempO-Seq's targeted approach.

TypeDirect peer
Description

US-based parent company of BioClavis and original developer of the TempO-Seq platform. Directly comparable as the originating licensor and North American commercial arm of the same technology stack BioClavis delivers in the UK and Europe.

TypeBroad incumbent
Description

Global provider of sample-preparation technologies and molecular diagnostics, including the QIAseq targeted sequencing portfolio. Comparable as a sample-tech and molecular diagnostics incumbent whose targeted-sequencing kits overlap with TempO-Seq use cases in pharma and clinical research.

TypeDirect peer
Description

Cancer genomics services company offering tumor profiling and molecular diagnostic solutions including the NeXT Personal assay. Comparable as a services-led molecular profiling business serving pharma and clinical research customers with custom biomarker panels.

TypeEmerging player
Description

Emerging single-cell transcriptomics company offering the PIPseq platform with a low-cost, scalable workflow. Comparable as a newer entrant targeting the same single-cell genomics and transcriptomics use cases that BioClavis is pursuing with TempO-LINC.

TypeBroad incumbent
Description

Global life science tools provider offering ddPCR, single-cell platforms (e.g., ddSEQ), and molecular biology reagents. Comparable as a broader portfolio provider of molecular profiling tools with overlapping pharma and academic research customer segments.

TypeDirect peer
Description

Developer of nCounter and GeoMx Digital Spatial Profiling platforms for targeted transcriptomics and gene expression. Direct competitor in the targeted-gene-expression space with overlapping pharma and academic customer use cases for biomarker discovery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioClavis

Genomics Servicesbioclavis.co.uk

BioClavis is a Glasgow-based R&D and services lab operating the proprietary TempO-Seq targeted-sequencing platform under license from parent BioSpyder Technologies, offering molecular profiling, biomarker discovery, and companion diagnostic services to pharmaceutical, academic, and clinical research customers across the UK, Europe, and APAC.

What BioClavis does

BioClavis, Ltd. is a Glasgow-based (Clydebank) privately held R&D and services laboratory founded in 2017 as a UK/European spin-out of US-based BioSpyder Technologies Inc., with shared founder/CEO Joel McComb across both entities. The company operates a single-site services model at Carus House, Clydebank, with a disclosed headcount of 1-10 employees and no disclosed external venture or private equity backing.

The company's core asset is the licensed TempO-Seq platform — a proprietary targeted-sequencing transcriptomic technology protected by an extensive multi-jurisdictional patent portfolio (US, UK, Europe, Singapore, Australia, Canada, India, New Zealand). TempO-Seq uses detector oligos that hybridize directly to expressed transcripts, eliminating the need for RNA extraction or reverse transcription and enabling profiling from difficult sample types including FFPE tissue (validated up to 30+ years old), crude cell lysates, whole blood, dried blood spots, and single cells. Product variants built on this core chemistry include TempO-LINC (single-cell, launched February 2024), TempO-SPan (high-throughput diagnostic testing including COVID-19), TempO-Seq FFPE, TempO-Seq Dried Blood Spot, and TempO-Seq miRNA, supported by modular pre-designed and custom gene panels and the TempO-Seq Portal cloud analysis tool.

BioClavis generates revenue primarily through professional services — molecular profiling, bioinformatics, and contract research for pharmaceutical drug discovery and companion diagnostic development, academic researchers, and clinical research organizations — supplemented historically by a £30/sample COVID-19 testing service launched December 2020. Distribution of TempO-Seq kits is handled via an authorized distributor network covering Spain, South Korea, Japan, Hong Kong, and Thailand, with BioSpyder Inc. serving North America. Strategic positioning is reinforced through participation in EU-funded consortia including RISK-HUNT3R (Horizon2020, 2021) and BRECISE (IHI/Horizon Europe, 2025).

BioClavis firmographics

Firmographics
Name
BioClavis
Legal name
BioClavis, Ltd.
Website
https://bioclavis.co.uk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
BioClavis is a Glasgow-based R&D and services lab operating the proprietary TempO-Seq targeted-sequencing platform under license from parent BioSpyder Technologies, offering molecular profiling, biomarker discovery, and companion diagnostic services to pharmaceutical, academic, and clinical research customers across the UK, Europe, and APAC.
Ownership category
akta.pro rank

BioClavis industry classification

Industry
Product category
Genomics Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Transcriptomic profiling services
  • Targeted gene expression
  • Biomarker discovery services
  • Companion diagnostic development
  • High-throughput sequencing

Where BioClavis is headquartered

Location

Headquarters

HQ city
Clydebank
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

BioClavis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

  1. Molecular Profiling Services: Lab services providing TempO-Seq transcriptomic and genomic analysis for drug discovery, biomarker discovery, and precision medicine applications. Services include high-throughput transcriptomics, companion diagnostic development, and clinical research support.
  2. Bioinformatics Services: Additional analysis services including probe design, exploratory data analysis, differential gene expression analysis, machine learning classification, pathway analysis, and single-cell analysis.
  3. COVID-19 Testing Services: TempO-SPan based COVID-19 testing service offered to businesses and organizations at £30 per sample price point for routine screening.

Pricing tiers

ModelBillingPrice
Usage-basedPay-as-you-goCOVID-19 Testing Service

Go-to-market motion3 records

Distribution channels7 records

Marketing channels6 records

BioClavis product offering

Product offering

Core offering

BioClavis operates a Glasgow-based R&D and services laboratory that delivers TempO-Seq-based molecular profiling to pharmaceutical, academic, and clinical research customers. The company provides high-throughput transcriptomics, biomarker discovery, companion diagnostic development, and COVID-19 variant surveillance, packaged with cloud bioinformatics through the TempO-Seq Portal. Its offerings also include customizable gene-expression panels, dried blood spot and FFPE workflows, and the TempO-LINC single-cell platform.

Product overview

BioClavis offers a unified platform-plus-services model centered on TempO-Seq, a proprietary high-throughput targeted-sequencing transcriptomic technology that eliminates the need for RNA extraction or reverse transcription. The core TempO-Seq platform serves as the foundation for specialized assay products including TempO-Seq Dried Blood Spot (DBS), TempO-Seq FFPE, and TempO-Seq miRNA, each adapted for specific sample types. TempO-LINC extends the platform into single-cell genomics applications. The company provides modular assay panels (Whole Transcriptome, S1500+ Surrogate, PanCancer, and Custom) for multiple species, supported by bioinformatics services including probe design, differential expression analysis, and machine learning classification. Services span pharma (drug discovery, companion diagnostics), academic research, and clinical research applications. The ecosystem is unified by TempO-Seq Portal cloud-based data analysis software.

Differentiator

Problem solved

Functional benefit

Brands

  • TempO-Seq: High-throughput targeted-sequencing transcriptomic/genomic platform technology for molecular analysis
  • TempO-LINC
  • TempO-Span
  • TempO-Seq DBS

Products and services

  • TempO-Seq Targeted, high-throughput transcriptomics platform using Detector Oligo chemistry to profile gene expression in a single assay, sold as a profiling service and kit to pharmaceutical and academic researchers.
  • TempO-LINC Single-cell gene-expression profiling platform built on combinatorial split-pool barcoding, extending TempO-Seq chemistry to individual cells for pharma and academic customers.
  • TempO-Span SARS-CoV-2 testing and variant surveillance panel built on TempO-Seq chemistry, offered as a per-sample COVID-19 testing service with results delivered through the TempO-Seq Portal.
  • TempO-Seq Portal Cloud-based bioinformatics platform that performs QC and gene-expression analysis on TempO-Seq data and delivers standardized reporting to research and clinical customers.
  • Pharma Services Dedicated TempO-Seq profiling service for pharmaceutical R&D teams, supporting drug discovery, mechanism-of-action studies, lead prioritization, and translational biomarker work.
  • Academic Research Services TempO-Seq profiling services tailored for academic and university research groups, including customizable panels and cloud-based analysis via the TempO-Seq Portal.
  • Clinical Research Services TempO-Seq clinical research service designed for clinical research organizations and translational sponsors needing validated profiling of FFPE and other clinical samples.
  • Bioinformatics Services Bespoke bioinformatics and gene-expression analysis services delivered alongside TempO-Seq profiling projects, with reporting routed through the TempO-Seq Portal.
  • Personalised Diagnostics Bespoke diagnostic development service that applies TempO-Seq chemistry to build companion and personalised diagnostics for pharmaceutical and clinical partners.
  • High-Throughput Transcriptomics (HTTr) Scalable, high-volume gene-expression profiling service using TempO-Seq chemistry for customers requiring large numbers of samples and reproducible data turnaround.

Quantifiable outcome

  • R2 = 0.97 correlation between FFPE and fresh frozen samples
  • +4 more outcomes

Companies that use BioClavis

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

BioClavis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature11 records

BioClavis partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • BRECISE Project ConsortiumcoreStrategic or Co-development Partner · 1 January 2025BioClavis joined the BRECISE project as an industry partner - a five-year research initiative co-funded by the Innovative Health Initiative (IHI) and Horizon Europe. The project focuses on precision oncology for prostate and bladder cancer using NGS-based multi-modality AI biomarkers. BioClavis contributes TempO-Seq for molecular analysis and biomarker identification.
  • RISK-HUNT3R ConsortiumcoreStrategic or Co-development Partner · 1 June 2021BioClavis joined the Horizon2020-funded RISK-HUNT3R project alongside 36 partners including academic researchers, regulatory authorities, and safety scientists from Pharma and Cosmetics sectors. The five-year project aims to develop animal-free chemical safety assessment methods using TempO-Seq for high-throughput transcriptomics on in vitro cell models.
  • BioSpyder Technologies Inc.coreOEM/ Whitelabel/ Licensing Partner · 1 January 2017BioClavis is a spin-out of US-based BioSpyder Technologies. The company leverages the proprietary TempO-Seq targeted-sequencing transcriptomic/genomic platform technology under license for precision diagnostics and drug discovery services. Joel McComb is CEO and founder of both companies.
  • NHS and Academic ResearchersminorStrategic or Co-development PartnerBioClavis maintains close collaborations with NHS and academic researchers to develop diagnostic solutions at the center of patient and healthcare system needs.
  • Collaboration Partners (Various Fields)minorStrategic or Co-development PartnerBioSpyder actively seeks collaborators in Liquid Biopsy, Toxicology/Metabolism, Oncology, Mental Health, Metabolic Diseases, Allergy, Host Defense, and Agriculture for TempO-Seq applications.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

BioClavis competitors and assessment

Company assessment

Broad incumbents

  • Eurofins Genomics: Part of Eurofins Scientific, one of the world's largest genomics services providers offering DNA/RNA sequencing, oligonucleotide synthesis, and bioinformatics. Comparable as a broader-scale genomics services lab serving pharma and academic customers with overlapping transcriptomics offerings.
  • Illumina: Dominant sequencing platform vendor whose instruments underpin most RNA-seq and targeted sequencing workflows. Comparable as the underlying sequencing technology provider whose installed base defines the competitive context for TempO-Seq's targeted approach.
  • Qiagen: Global provider of sample-preparation technologies and molecular diagnostics, including the QIAseq targeted sequencing portfolio. Comparable as a sample-tech and molecular diagnostics incumbent whose targeted-sequencing kits overlap with TempO-Seq use cases in pharma and clinical research.
  • Bio-Rad Laboratories: Global life science tools provider offering ddPCR, single-cell platforms (e.g., ddSEQ), and molecular biology reagents. Comparable as a broader portfolio provider of molecular profiling tools with overlapping pharma and academic research customer segments.

Direct peers

  • 10x Genomics: Leading single-cell genomics platform company offering Chromium and Visium products. Direct competitor to BioClavis's newly launched TempO-LINC single-cell platform with overlapping pharma and translational research customers.
  • Standard BioTools (formerly Fluidigm): Developer of mass cytometry and single-cell genomics platforms including the Hyperion and Biomark systems. Direct competitor in high-throughput single-cell and targeted transcriptomics for pharma and academic research applications.
  • BioSpyder Technologies: US-based parent company of BioClavis and original developer of the TempO-Seq platform. Directly comparable as the originating licensor and North American commercial arm of the same technology stack BioClavis delivers in the UK and Europe.
  • Personalis: Cancer genomics services company offering tumor profiling and molecular diagnostic solutions including the NeXT Personal assay. Comparable as a services-led molecular profiling business serving pharma and clinical research customers with custom biomarker panels.
  • NanoString Technologies: Developer of nCounter and GeoMx Digital Spatial Profiling platforms for targeted transcriptomics and gene expression. Direct competitor in the targeted-gene-expression space with overlapping pharma and academic customer use cases for biomarker discovery.

Emerging players

  • Fluent BioSciences: Emerging single-cell transcriptomics company offering the PIPseq platform with a low-cost, scalable workflow. Comparable as a newer entrant targeting the same single-cell genomics and transcriptomics use cases that BioClavis is pursuing with TempO-LINC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

BioClavis social profiles

Digital presence

BioClavis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioClavis leadership team

Management profile

Number of profiles

Profiles3 records

BioClavis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioClavis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioClavis

What does BioClavis do?

BioClavis operates a Glasgow-based R&D and services laboratory that delivers TempO-Seq-based molecular profiling to pharmaceutical, academic, and clinical research customers. The company provides high-throughput transcriptomics, biomarker discovery, companion diagnostic development, and COVID-19 variant surveillance, packaged with cloud bioinformatics through the TempO-Seq Portal. Its offerings also include customizable gene-expression panels, dried blood spot and FFPE workflows, and the TempO-LINC single-cell platform.

Is BioClavis a public or private company?

BioClavis is a private company. It is classified as corporate owned and is currently operating.

When was BioClavis founded?

BioClavis was founded in 2017. It employs 11 to 50 people.

Where is BioClavis based?

BioClavis is headquartered in Clydebank, United Kingdom, in the Europe region.

How does BioClavis make money?

Three revenue lines are on record. Molecular Profiling Services are the primary driver. The others are bioinformatics Services and COVID-19 Testing Services.

Who are BioClavis's main competitors?

Broad incumbents on record are Eurofins Genomics, Illumina, Qiagen and Bio-Rad Laboratories. Direct peers are 10x Genomics, Standard BioTools (formerly Fluidigm), BioSpyder Technologies, Personalis and NanoString Technologies. Fluent BioSciences is listed as an emerging player.

Does BioClavis have an API?

No public API is recorded for BioClavis.

What industry is BioClavis in?

BioClavis's product category is Genomics Services. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales